1 min read
Aytu BioPharma Agrees to Rosemont Buyout at $2.70 Per Share
A wholly owned Rosemont subsidiary plans to make a cash offer for all of Aytu’s outstanding common shares.

Aytu BioPharma, Inc. has agreed to a cash acquisition by Rosemont Pharmaceuticals at $2.70 per share, with the transaction structured as a tender offer covering the company’s outstanding common stock.
The definitive merger agreement calls for Rosemont to make the offer through a subsidiary it wholly owns. The bid would cover every Aytu common share still outstanding.
The acquisition remains pending. The subsidiary is to begin the tender offer under the agreement.